Ranbaxy Lipitor Settlement With Pfizer Could Double Indian Firm Sales
This article was originally published in PharmAsia News
Executive Summary
The patent suit settlement Pfizer against Ranbaxy Laboratories could mean sales by India's largest drug maker will double within the next three years. The settlement ended Pfizer's suit against Ranbaxy and its generic of the U.S. company's Lipitor (atorvastatin). Last year, Lipitor brought $12.7 billion in sales to Pfizer, so the settlement allowing Ranbaxy to market a generic ahead of the expiration date for the drug patent could earn the Indian drug maker $2 billion, more than the firm's $1.78 billion in sales last year. Ranbaxy is allowed to begin marketing its generic in Canada after Nov. 30, and in the U.S. after Nov. 30, 2011. (Click here for more
You may also be interested in...
Ranbaxy Forecasts Conservative Growth, Remains Silent On Atorvastatin Launch, U.S. FDA Action
MUMBAI - Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. took analysts in India by surprise with a forecast of a very conservative growth target that did not factor in any upside from a possible launch of a generic version of Lipitor (atorvastatin) in the U.S
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.